Targeting eradication of malignant cells derived from human bone marrow mesenchymal stromal cells

Experimental Cell Research

Volumn 316, Issue 20, 2010, Pages 3329-3341

  Yang, Yingbin ^a,b   Cai, Shaoxi ^a   Yang, Li ^a,f   Yu, Shuhui ^a,b   Jiang, Jiahuan ^a   Yan, Xiaoqing ^a   Zhang, Haoxing ^b   Liu, Lan ^c   Liu, Qun ^d   Du, Jun ^e   Cai, Shaohui ^f   Sung, K L Paul ^a,g  

^a CHONGQING UNIVERSITY   (China)

^b SOUTHWEST UNIVERSITY   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d SOUTHWEST UNIVERSITY FOR NATIONALITIES   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f JINAN UNIVERSITY   (China)

^g University of California   (United States)

Author keywords

HBMSC; HTERT promote; Malignant transformation; Targeting eradication

Indexed keywords

CYTOSINE DEAMINASE; DIHYDROXYBENZO[A]PYRENE OXIDE; FLUCYTOSINE; LENTIVIRUS VECTOR; LUCIFERASE; MYC PROTEIN; MYELOID ZINC FINGER PROTEIN 2; SPARFOSIC ACID; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CULTURE; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; ESCHERICHIA COLI; FEMALE; GENE FUSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN BONE MARROW MESENCHYMAL STROMAL CELL; HUMAN CELL; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; STROMA CELL; TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM;

EID: 78149408348     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.02.014     Document Type: Article

References (31)

1. Kiuru M., Boyer J.L., O'Connor T.P., Crystal R.G. Genetic Control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell 2009, 4:289-300.
2. Houghton J.M., Stoicov C., Nomura S., Rogers A.B., Carlson J., Li H., Cai X., Fox J.G., Goldenring J.R., Wang T.C. Gastric cancer originating from bone marrow-derived cells. Science 2004, 306:1568-1571.
3. Rubio D., Garcia-Castro J., Martín M.C., Martín, De la Fuente R., Lloyd A.C., Bernad A. Spontaneous human adult stem cell transformation. Cancer Res. 2005, 65:3035-3039.
4. Rossi D.J., Weissman I.L. Pten, tumorigenesis and stem cell self-renewal. Cell 2006, 125:229-231.
5. Avital I., Moreira A.L., Klimstra D.S., Leversha M., Papadopoulos E.B., Brennan M., Downey R.J. Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 2007, 25:2903-2909.
6. Izadpanah R., Kaushal D., Kriedt C., Tsien F., Patel B., Dufour J., Bunnell B.A. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res. 2008, 68:4229-4238.
7. Akimoto M., Miyahara T., Arai J., Hamada H., Yoshida Y., Yoshida Y., Yoshimura N. A new delivery system for 5-fluorouracil using prodrug and converting enzyme. Br. J. Ophthalmol. 2002, 86:581-586.
8. Ge K., Xu L., Zheng Z., Xu D., Sun L., Liu X. Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Int. J. Cancer 1997, 71:675-679.
9. Carroll S. Evolution at two levels: on genes and form. PLoS Biol. 2005, 3:1159-1166.
10. Kinkhabwala A., Guet C.C. Uncovering cis regulatory codes using synthetic promoter shuffling. PLoS ONE 2008, 3:e2030. 10.1371/journal.pone.0002030.
11. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
12. Komata T., Koga S., Hirohata S., Takakura M., Germano I.M., Inoue M., Kyo S., Kondo S., Kondo Y. A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int. J. Oncol. 2001, 19:1015-1020.
13. Sommer A., Bousset K., Kremmer E., Austen M., Luscher B. Identification and characterization of specific DNA-binding complexes containing members of the Myc/Max/Mad network of transcriptional regulators. J. Biol. Chem. 1998, 273:6632-6642.
14. Yang Y.-B., Cai S.-X., Yu S.-H., Yang L., Li J., Yu S.-T., Dai X.-Z., Wang X.-X., Yan X.-Q., Xin X., Sung K.L.P. hTERT core promoter modified by E-boxes element and transcriptional activity assay in vitro. Chin. J. Biochem. Mol. Biol. 2009, 25:510-514.
15. Fujimoto K., Kyo S., Takakura M., Kanaya T., Kitagawa Y., Itoh H., Takahashi M., Inoue M. Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT. Nucleic Acids Res. 2000, 28:2557-2562.
16. Bernardo M.E., Zaffaroni N., Novara F., Cometa A.M., Avanzini M.A., Moretta A., Montagna D., Maccario R., Villa R., Daidone M.G., Zuffardi O., Locatelli F. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007, 67:9142-9149.
17. Else T., Trovato A., Kim A.C., Wu Y., Ferguson D.O., Kuick R.D., Lucas P.C., Hammer G.D. Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell 2009, 15:465-476.
18. Wang Y., Yang J., Zheng H., Tomasek G.J., Zhang P., McKeever P.E., Lee E.Y.-H.P., Zhu Y. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 2009, 15:514-526.
19. Jin Z., May W.S., Gao F., Flagg T., Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J. Biol. Chem. 2006, 281:14446-14456.
20. Foddis R., De Rienzo A., Broccoli D., Bocchetta M., Stekala E., Rizzo P., Tosolini A., Grobelny J.V., Jhanwar S.C., Pass H.I., Testa J.R., Carbone M. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene 2002, 21:1434-1442.
21. Xu W., Zhang X., Qian H., Zhu W., Sun X., Hu J., Zhou H., Chen Y. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp. Biol. Med. 2004, 229:623-631.
22. Perwez Hussain S., Amstad P., Raja K., Sawyer M., Hofseth L., Shields P.G., Hewer A., Phillips D.H., Ryberg D., Haugen A., Harris C.C. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res. 2001, 61:6350-6355.
23. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72:8463-8471.
24. Chernova O.B., Chernov M.V., Ishizaka Y., Agarwal M.L., Stark G.R. MYC abrogates p53-mediated cell cycle arrest in N-(Phosphonacetyl)-l-aspartate-treated cells, permitting CAD gene amplification. Mol. Cell. Biol. 1998, 18:536-545.
25. Agarwal M.L., Agarwal A., Chernova O., Sharma Y., Stark G.R. A p53-dependent s-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. PNAS 1998, 95:14775-14780.
26. Miura M., Miura Y., Padilla-Nash H.M., Molinolo A.A., Fu B., Patel V., Seo B.M., Sonoyama W., Zheng J.J., Baker C.C., Chen W., Ried T., Shi S. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006, 24:1095-1103.
27. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008, 118:3367-3377.
28. Kuroki T., Huh N.-H. Why are human cells resistant to malignant cell transformation in vitro?. Jpn. J. Cancer Res. 1993, 84:1091-1100.
29. Zeamari S., Rumping G., Floot B., Lyons S., Stewart F.A. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. Br. J. Cancer 2004, 90:1259-1264.
30. Hart L.S., El-Deiry W.S. Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. JCO 2008, 26:2901-2910.
31. Rose G.S., Tocco L.M., Granger G.A., Disaia P.J., Hamilton T.C., Santin A.D., Hiserodt J.C. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am. J. Obstet. Gynecol. 1996, 175:593-599.